LGR4 Deficiency Aggravates Skin Inflammation and Epidermal Hyperplasia in Imiquimod‐Induced Psoriasis
Immunology · 2025-02 · 174 (2) · 213-225
DOI: 10.1111/imm.13873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 20.11.2024. Verfasst von Mengfei Xue und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Psoriasis, Receptors, G-Protein-Coupled, Mice, Knockout, Imiquimod. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Shanghai Oriental Talent Plan Project.
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disease characterised by inflammatory cell infiltration, keratinocyte hyperproliferation and increased neovascularization. Despite extensive research, the precise mechanisms underlying psoriasis pathology and treatment strategies remain unclear because of a complex aetiology and disease progression. Hence, in this study, we aimed to identify potential therapeutic targets for psoriasis and explore their effects on disease progression. We observed that G protein‐coupled receptor LGR4 attenuates psoriasis progression. Bioinformatics analysis of publicly available clinical data revealed lower LGR4 expression in the skin lesions of patients with psoriasis than in their non‐lesioned skin. Both in vitro (HaCaT cell) and in vivo (mouse) models confirmed this phenomenon. The Lgr4 ‐knockout mouse model further confirmed that LGR4 plays a positive role in psoriasis progression. Specifically, Lgr4 knockout promoted the secretion of inflammatory factors, accumulation of local immunocyte infiltration in skin lesions, and keratinocyte proliferation. In conclusion, we demonstrated that LGR4 is critical to limiting psoriasis progression, suggesting that it is a viable target for the clinical management of this skin condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Fengxian District Central Hospital, School of Medicine, Anhui University of Science and Technology, Shanghai, China.
- Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai, China.
- Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Mengfei Xue, Ruijie Yang, Yuqing Chao, Juliang Qin, Zhenliang Sun
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Shanghai Oriental Talent Plan Project
- Science and Technology Commission of Shanghai Municipality
- Shanghai University of Medicine & Health Sciences Seed Fund
- Medical Key Disciplines of Shanghai Municipal Health Commission
- National Key Research and Development Program of China
Zitieren
APA
Xue, M., Yang, R., Li, G., Ni, Z., Chao, Y., Shen, K., Ren, H., Du, B., Qin, J., & Sun, Z. (2025). LGR4 Deficiency Aggravates Skin Inflammation and Epidermal Hyperplasia in Imiquimod‐Induced Psoriasis. Immunology, 174(2), 213-225. https://doi.org/10.1111/imm.13873
Vancouver
Xue M, Yang R, Li G, Ni Z, Chao Y, Shen K, et al. LGR4 Deficiency Aggravates Skin Inflammation and Epidermal Hyperplasia in Imiquimod‐Induced Psoriasis. Immunology. 2025;174(2):213-225. doi:10.1111/imm.13873
BibTeX
@article{Xue2025,
author = {Xue, Mengfei and Yang, Ruijie and Li, Guihong and Ni, Zhizhan and Chao, Yuqing and Shen, Kairui and Ren, Hua and Du, Bing and Qin, Juliang and Sun, Zhenliang},
title = {LGR4 Deficiency Aggravates Skin Inflammation and Epidermal Hyperplasia in Imiquimod‐Induced Psoriasis},
journal = {Immunology},
year = {2025},
volume = {174},
number = {2},
pages = {213--225},
doi = {10.1111/imm.13873}
}
EUVIMED